OPTI.CN

Optimi Health Corp.

Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats

Optimi Health Corp.VANCOUVER, British Columbia, Jan. 03, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, proudly announces a significant milestone in the granting of i... Read More...

Optimi Health Resolves Dispute

VANCOUVER, British Columbia, Nov. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply Agreement") signed with a private entity on May 4, 2023. Optimi is pl... Read More...

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

VANCOUVER, British Columbia, Sept. 14, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Compan... Read More...

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

VANCOUVER, British Columbia, Sept. 05, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it... Read More...

Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement

Optimi Health Corp.The announcement follows a national reclassification of MDMA and psilocybin for therapeutic uses in Australia as a result of the years-long effort of Mind Medicine Australia and its dedicated supportersHighlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-t... Read More...

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Optimi Health Corp.EU-GMP, operational, and service excellence to drive world-class sales pipelineFunctional MushroomsFunctional mushrooms grown at Optimi Health facility in Princeton, British Columbia.Lion's ManeLion's Mane mushrooms grown at Optimi Health facility in Princeton, British Columbia.Optimi LifeOptimi Life BundleVANCOUVER, Br... Read More...

Optimi Health Provides Progress Report On Year Of Commercialization

Optimi Health Corp.Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertiseVANCOUVER, British Columbia, Sept. 01, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, ... Read More...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Corp.Deals position Optimi Life nutraceutical brand for international distributionOptimi LifeOptimi Life BundleOptimi LifeOptimi LifeOptimi LifeOptimi LifeVANCOUVER, British Columbia, Aug. 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by H... Read More...

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

VANCOUVER, British Columbia, Aug. 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experie... Read More...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

VANCOUVER, British Columbia, July 13, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that... Read More...

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

Optimi Health Corp.Optimi Health Cultivation and Analytical FacilitiesOptimi Health Cultivation and Analytical FacilitiesOptimi Health Fruiting RoomOptimi Health fruiting room being prepared for second grow.VANCOUVER, British Columbia, June 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), ... Read More...

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

VANCOUVER, British Columbia, May 31, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with ... Read More...

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

VANCOUVER, British Columbia, May 27, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with ... Read More...

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

Optimi Health Corp.Lab’s completion brings Company closer to full commercializationVANCOUVER, British Columbia, May 11, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, Briti... Read More...

Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin

VANCOUVER, British Columbia, May 09, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the... Read More...

Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

VANCOUVER, British Columbia, April 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders... Read More...

Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials

Optimi Health Corp.VANCOUVER, British Columbia, March 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.“These mushrooms are an important milest... Read More...

Optimi Health Announces Investor Relations Agreement

VANCOUVER, British Columbia, March 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce it has entered into agreements with Kydde... Read More...

Optimi Health Dealer’s License Granted by Health Canada

Optimi Health to become a global leader in all-natural psilocybin productionVANCOUVER, British Columbia, Feb. 07, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellne... Read More...

Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department

VANCOUVER, British Columbia, Dec. 21, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce a facility inspection under ... Read More...

Optimi Health Clears Final Base Shelf Prospectus

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Aug. 18, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to ... Read More...

Optimi Health Strengthens Clinical and Regulatory Expertise

VANCOUVER, British Columbia, July 27, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant t... Read More...